To what extent should papers submitted from drug companies be published in medical journals? Editorial

Acta Psychiatrica Scandinavica

Volumn 99, Issue 3, 1999, Pages 157-159

  Friis, S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; EDITORIAL; MEDICAL LITERATURE; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLICATION;

EID: 0033020710     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1999.tb00971.x     Document Type: Editorial

References (7)

1. 1 Nemeroff, CB. The escalating pharmaceutical company wars: where is an academic to hide CNS Spectrums 1998 ; 3: 17, 92.
2. 2 Lemmens, P, Brecher, M, Van Baelen, B. A combined analysis of double‐blind studies with risperidone versus placebo and other antipsychotic agents: factors associated with exlra‐pyramidal symptoms. Acta Psychiatr Scand 1999 ; 99: 160–170.
3. 3 Tran, PV, Hamilton, SH, Kuntz, AJ et al. Double‐blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 ; 17: 407–418.
4. 4 Schooler, NR. Comments on article by Tran and colleagues, ‘Double‐blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders’]. J Clin Psychopharmacol 1998 ; 18: 174–175.
5. 5 Tollefson, GD, Tran, PV. Reply. Letter to the editor. J Clin Psychopharmacol 1998 ; 18: 175–176.
6. 6 Gheuens, J, Grebb, JA. Comments on article by Tran and colleagues, ‘Double‐blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders’]. J Clin Psychopharmacol 1998 ; 18: 176–177.
7. 7 Tollefson, GD, Tran, PV. Reply. Letter to the editor. J Clin Psychopharmacol 1998 ; 18: 177–179.